The SMC has announced that dulaglutide and albiglutide, two once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists, have been approved for use as add-on therapy in Scotland. Both are licensed in combination with other glucose-lowering therapies, including insulin, when these fail to achieve adequate glycaemic control in conjunction with diet and exercise.
Dulaglutide 1.5mg (Trulicity®; Eli Lilly and Company) is approved as part of triple therapy in people with inadequate glycaemic control on two oral anti-diabetic drugs, as an alternative GLP-1 receptor agonist option. The SMC has not reviewed the agent for its other indication – as monotherapy in people for whom metformin is contraindicated – and currently does not recommend it for this use.
Albiglutide (Eperzan®; GlaxoSmithKline) is approved as an alternative once-weekly GLP-1 receptor agonist for use in combination with oral anti-diabetes agents as a third-line pre-insulin treatment option. The SMC has not reviewed and does not recommend its use as monotherapy.